Condition
Malignant Pleural Mesothelioma
Estimated Enrollment: 31
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment
Study ID Numbers: 10-134
Study First Received: December 21, 2010
Last Updated: January 4, 2017
Estimated Primary Completion Date: December 2017
Primary Outcome Measures:
To assess the 1-year progression free survival in patients|To confirm the immunogenicity of the WT-1 analog peptide vaccine|To assess the utility of using the serum marker|overall survival
Sponsors and Collaborators:
Memorial Sloan Kettering Cancer Center|United States Department of Defense
Website Link: https://ClinicalTrials.gov/show/NCT01265433
